Read Full Story Data science is at the core of modern business, impacting industries ranging from healthcare to government to advertising. In response to the growing demand, Harvard Online is announcing a new course, Data Science Ready, to help managers speak the language of data science and contribute to data-oriented discussions.The nearly code- and math-free, four-week online course will introduce prediction, causality, visualization, data wrangling, privacy, and ethics. Data Science Ready is a new Harvard Online course in collaboration with Harvard Business School Online (HBS Online). Delivered via the HBS Online course platform, it brings concepts to life using real-world examples, while prompting participants to think critically about how to apply those lessons in their own workplaces.Experts will speak firsthand about how data science is changing the landscape in their industry. They include:Brian Powers from Brigham and Women’s HospitalMauricio Santillana from Boston Children’s HospitalBen Ewen-Campen from the City of Somerville, Mass.Kade Crockford from the American Civil Liberties UnionDan Restuccia from Burning GlassFormer Boston Police Commissioner Ed DavisFaculty from Harvard University, the University of Pennsylvania, and the University of Chicago“It’s an analytical world, so to remain relevant and be successful in business today, you need a foundation in data science,” said Dustin Tingley, course instructor and Harvard University’s deputy vice provost for advances in learning. “We’ve designed this course for non-technical professionals to level the playing field and enable all managers to contribute and excel in data-oriented organizations.”In this course, participants will:Gain a fundamental understanding of data science, including the essential concepts, skills, and vocabulary needed to contribute effectively to data-oriented discussionsExplore predictions, causality, privacy, alternative data sources, data ecosystems, and big dataEnhance your learning through conversations with and feedback from a global network of peersAccess tools and techniques you can immediately apply on the jobApplications for the four-week course will be accepted through Jan. 14, 2021, and the course will begin on Jan. 27. Participants can expect to dedicate approximately five hours per week to the course material.For more information or to apply for the course, visit the Data Science Ready page.Affiliations are listed for identification purposes only.
The law says the HHS secretary can declare an emergency permitting the use of an unlicensed product if, among other circumstances, the secretary of defense determines that there is “a military emergency, or significant potential for a military emergency, involving a heightened risk” of attacks on US forces with a biological, chemical, radiological, or nuclear weapon. Oct 28, 2004, CIDRAP News story, “Court ruling again stops anthrax shots for US soldiers” HHS announced in early November that it would buy 5 million doses of BioThrax for the Strategic National Stockpile of drugs and medical supplies for civilian use. At the same time, the department announced plans to buy 75 million doses of a new, not-yet-licensed anthrax vaccine to protect the public. “It is essential that HHS consider this first request for Project BioShield Act authority carefully and with maximum public input to avoid even the implication that HHS will rubber stamp or give unquestioning, and undeserved, deference to DOD determinations on medical matters,” Shays states in the letter. In suspending the program, DoD officials said they were still convinced that the vaccine is safe. Wolfowitz asked Thompson to use his authority under Section 4 of the BioShield law, which says the HHS secretary can, in emergencies, authorize the use of drugs, medical devices, and biological products that have not been approved by the FDA. A federal judge ordered DoD to stop the vaccination program in October on grounds that the Food and Drug Administration (FDA) had not followed proper procedures in approving use of the vaccine to prevent inhalational anthrax. See also: Dec 21, 2004 (CIDRAP News) The US Department of Defense (DoD) has asked for emergency authority to ignore a recent court ruling and resume vaccinating military personnel against anthrax because of what is described as an increased risk of attacks on US forces. Sullivan ruled that the FDA violated its own procedures by not asking for public comments before approving the anthrax vaccine, called BioThrax (formerly Anthrax Vaccine Adsorbed), for inahalational anthrax. The judge cited a 1998 law that bars DoD from forcing personnel to take investigational or unapproved drugs unless the president decides that their consent isn’t necessary. “I have determined that there is a significant potential for a military emergency involving a heightened risk to United States military forces of attack with anthrax,” Wolfowitz wrote in the letter, a copy of which was provided by HHS officials. Request under reviewHHS officials are reviewing the DoD request, a department spokesman told CIDRAP News today. Marc Wolfson of the HHS Office of Public Health Emergency Preparedness in Washington wouldn’t predict how or when HHS might respond to the request. In a Dec 10 letter, Deputy Secretary of Defense Paul Wolfowitz asked Health and Human Services (HHS) Secretary Tommy Thompson for permission to resume the vaccination program. Wolfowitz cited the Project BioShield Act of 2004 as giving Thompson authority to grant the permission. “Such deference has not served our military well in the past, when DOD failed to meet conditions and commitments on the use of experimental products like pyridostigmine bromide,” the letter continues. “How will the department ensure the rigor and transparency of its deliberations regarding this matter?” Congressman questions DoD moveRep. Christopher Shays, R-Conn., has raised questions about the DoD request to resume giving the shots. In a Dec 16 letter to Thompson, Shays, vice-chairman of the House Government Reform Committee, said the request “presents a number of unique, potentially troubling, legal and procedural issues.” The letter concludes by asking, “Does HHS now consider the current anthrax vaccine product labeling incomplete or misleading in that it fails to differentiate between approved use for cutaneous exposure and unapproved use for inhalational exposure?” About 1.25 million military personnel have received anthrax shots since the vaccination program started in 1998, according to DoD, but some troops have refused the shots because of concern about side effects. The program was suspended after US District Judge Emmet G. Sullivan issued an injunction Oct 27 in a suit brought by six military members and military contractor employees. Shays goes on to say that “hundreds of military service personnel have suffered adverse reactions to the vaccine” and asks whether HHS will have access to the recent intelligence about the anthrax threat to US forces. “In making this determination, I have considered a November 2004 Intelligence Community assessment of the anthrax threat. This heightened risk has been and continues to be the basis for the DoD program of vaccinating personnel in the areas of the Central Command and Korea.” The letter does not give any details about the threat. read more
The game comes two weeks after their last meeting in the Premier League, in which Manchester City ran away with a 6-0 victory, but City manager Pep Guardiola does not think the game will have a bearing on today’s result.“I don’t like to play the same team in a short period of time when you have beaten them before,” he said.“They are incredibly professional players, they are proud and bright and will do extra. We are going to play the type of game you have to play in a final and try to win the title.“Of course it is not the most important title of the season but once we are here in an amazing stadium against a top side, we want to prepare to win.”Chelsea made it into the last 16 of the Europa League on Thursday, but Sarri says his side cannot make the same sluggish start as they did against Malmo at Stamford Bridge.“It would be a disaster, of course. I think that we played the first 30 minutes without confidence. Nervous. We were unable to move the ball very fast. We were in trouble on their pressing. Then a little bit better in the last 15 minutes of the first half and then, after the first goal, very well.”John Stones (groin), Benjamin Mendy (knee) and Gabriel Jesus (hamstring) are doubtful for today’s final and Guardiola refused to confirm if Arijanet Muric – who has played in goal in the previous rounds – would start ahead of Ederson.There are also question marks over who will be Chelsea’s goalkeeper at Wembley, with Kepa Arrizabalaga missing Thursday’s Europa League game with a hamstring injury. Should he be sidelined again, former Man City goalkeeper Willy Caballero will deputise in his place.Pedro and Davide Zappacosta have also been suffering with illness this week and are doubtful.Both teams are set to face-off in a League Cup final for the first time – both sides have won the trophy five times previously, with only Liverpool winning it more often (eight times).Chelsea have already lost three times at Wembley this season, losing in the Community Shield against Manchester City and in the Premier League and League Cup semi-final against Spurs.Manchester City striker Gabriel Jesus has scored more goals than any other player in this season’s League Cup (5) – but all five have come against League One sides (one v Oxford, four v Burton).Should one, or more, of Manchester City trio David Silva, Vincent Kompany and Sergio Aguero score, they could become the first players to score in back-to-back League Cup finals since Didier Drogba did so for Chelsea in 2006-07 and 2007-08.Sergio Aguero has scored 13 goals in 16 appearances in all competitions against Chelsea for Manchester City, only scoring more often against Newcastle United for the Citizens (15).Share this:FacebookRedditTwitterPrintPinterestEmailWhatsAppSkypeLinkedInTumblrPocketTelegram Under fire manager Maurizio Sarri leads a stuttering Chelsea side against rampant Manchester City in the Carabao Cup final at Wembley Saturday.This is against a backdrop of rumours that the Blues are searching for Sarri’s replacement, with England’s assistant manager, Steve Holland, the latest name being mentioned.City won the competition last year and will be looking to defend their title for the first time, while a final win would ease the pressure on Sarri and Chelsea. Maurizio Sarri read more